CTRI/2017/02/007957CompletedPhase 3
Edaravone-based intervention in spinal cord injury through modulation of superoxide dismutase (SOD) and catalase (CAT) gene expression
Rajeshwar Nath Srivastava0 sites96 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Enrollment
- 96
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •Age 16-65, either gender, Vertebral fracture T8-L1, Neurological Involvement (Association Impairment Scale (AIS-B-D), Duration of Injury < 72 hours.
Exclusion Criteria
- •Associated injuries such as limb fractures, thoraco-abdominal injuries, head injuries and Pre-existing central or peripheral neurologic diseases (i.e. previous stroke, radiculopathy or polyneuropathy) needing intervention were excluded.
Investigators
Similar Trials
Not yet recruiting
Phase 3
Effectivnes of edaravone on ischemic strokeIschemic stroke.Cerebral infarctionIRCT20240224061102N1Yasouj University of Medical Sciences60
Not yet recruiting
Phase 2
Phase 2 study of treatment for spinal cord injury(ASIA impairment scale A,B) with autologous mononuclear cells derived from bone marrowSpinal cord injuryJPRN-UMIN000015741Department of plastic surgery, Kitano hospital20
Completed
Phase 1
The Safety of Edaravone for patients with Amyotrophic Lateral Sclerosis: Single centered open label trialamyotrophic lateral sclerosisJPRN-UMIN000016352Ehime University Hospital10
Completed
Not Applicable
Clinical study of the effectiveness of edaravone for the oxidative stress in amyotrophic lateral sclerosisAmyotrophic Lateral Sclerosis (ALS)JPRN-UMIN000024854Okayama university20
Active, not recruiting
Not Applicable
Study of Edaravone as adjunctive treatment in COVIDCTRI/2020/10/028472Sparsh Foundation